



## **Editas Medicine Announces Transition of Chief Financial Officer**

December 21, 2018

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D., Ph.D., will be stepping down from the Company, effective March 1, 2019, to return to the investment industry. A search is underway to find a successor to Dr. Hack.

"I want to thank Andrew for his distinguished service to the organization, as well as to the broader field of genome editing," said Katrine Bosley, President and Chief Executive Officer, Editas Medicine. "Andrew has played an important role building a sustainable and valued business at Editas Medicine and preparing us for the bright future we believe lies ahead. We wish him all the best as he returns to his passion of investing in growing life science companies, and we look forward to working with him on a smooth transition."

"I'm fortunate to have been able to contribute to building Editas Medicine during a truly remarkable time for both the Company and the field of genome editing," stated Dr. Hack. "I am pleased to have been part of the success of the organization, and believe that, with the FDA acceptance of our IND for our LCA10 program, this is a natural transition point. I look forward to watching Editas Medicine's future success in the years ahead."

### **About Editas Medicine**

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit [www.editasmedicine.com](http://www.editasmedicine.com).

### **Forward-Looking Statements**

This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

### **Contacts:**

#### **Media**

Cristi Barnett  
(617) 401-0113  
[cristi.barnett@editasmed.com](mailto:cristi.barnett@editasmed.com)

#### **Investors**

Mark Mullikin  
(617) 401-9083  
[mark.mullikin@editasmed.com](mailto:mark.mullikin@editasmed.com)



Source: Editas Medicine, Inc.